REGENXBIO (RGNX) Expected to Release Quarterly Earnings on Thursday

REGENXBIO (NASDAQ:RGNX) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect REGENXBIO to announce earnings of ($1.2873) per share and revenue of $10.89 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.35. The business had revenue of $108.02 million for the quarter, compared to analyst estimates of $97.63 million. REGENXBIO had a negative return on equity of 220.07% and a negative net margin of 112.58%. On average, analysts expect REGENXBIO to post ($3.65) EPS for the current fiscal year and ($2.94) EPS for the next fiscal year.

REGENXBIO Price Performance

Shares of RGNX opened at $7.63 on Wednesday. The firm’s 50 day simple moving average is $7.90 and its 200 day simple moving average is $9.15. The company has a market capitalization of $503.66 million, a P/E ratio of -2.01 and a beta of 1.24. REGENXBIO has a 1-year low of $5.45 and a 1-year high of $16.19.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on RGNX shares. HC Wainwright reissued a “buy” rating on shares of REGENXBIO in a research note on Monday, September 28th. Mizuho began coverage on shares of REGENXBIO in a report on Monday, October 5th. They set an “outperform” rating and a $22.00 price target for the company. Robert W. Baird dropped their price objective on REGENXBIO from $32.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, August 25th. Zacks Research raised shares of REGENXBIO from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Barclays cut REGENXBIO from an “overweight” rating to a “hold” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $23.17.

REGENXBIO Company Profile

REGENXBIO Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company’s programs use adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells, with the goal of addressing the underlying causes of disease rather than primarily treating symptoms.

REGENXBIO’s technology is built around its NAV AAV Technology Platform, which supports the design and development of gene-delivery vectors. Its pipeline has included investigational therapies for conditions such as Duchenne muscular dystrophy, Hunter syndrome, age-related macular degeneration and other rare diseases.